TransMedics Group is trading at $85.53, up +4.08%, as healthcare gains 1.28%, suggesting defensive sector rotation is supporting the move.
- No new company-specific announcement directly explains the September 14, 2026 rise; the advance therefore appears primarily sector-driven.
- Management is scheduled to speak at the Morgan Stanley Global Healthcare Conference at 3:20 p.m. EST, providing additional investor attention; it previously reaffirmed 2026 revenue guidance of $737 million–$757 million.